RET and chronic myelogenous leukemia, BCR-ABL1 positive: Since the US FDA approved imatinib for the treatment of chronic myeloid leukemia in 2001, multiple potent and well-tolerated TKIs—with targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT—have emerged and contributed to significant progress in cancer treatment.